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Candida species are the leading causes of invasive fungal infection among hospitalized patients and are responsible for major
economic burdens. The goals of this study were to estimate the costs directly associated with the treatment of candidemia and
factors associated with increased costs, as well as the impact of first-line antifungal agents on the outcomes and costs. A retro-
spective study was conducted in a sample of 199 patients from four university-affiliated tertiary care hospitals in Korea over 1
year. Only costs attributable to the treatment of candidemia were estimated by reviewing resource utilization during treatment.
Risk factors for increased costs, treatment outcome, and hospital length of stay (LOS) were analyzed. Approximately 65% of the
patients were treated with fluconazole, and 28%were treated with conventional amphotericin B. The overall treatment success
rate was 52.8%, and the 30-day mortality rate was 47.9%. Hematologic malignancy, need for mechanical ventilation, and treat-
ment failure of first-line antifungal agents were independent risk factors for mortality. The mean total cost for the treatment of
candidemia was $4,743 per patient. Intensive care unit stay at candidemia onset and antifungal switch to second-line agents were
independent risk factors for increased costs. The LOS was also significantly longer in patients who switched antifungal agents to
second-line drugs. Antifungal switch to second-line agents for any reasons was the only modifiable risk factor of increased costs
and LOS. Choosing an appropriate first-line antifungal agent is crucial for better outcomes and reduced hospital costs of
candidemia.
Invasive fungal infections by Candida species have become in-creasingly important worldwide. They are the fourthmost com-
mon cause of nosocomial bloodstream infections in the United
States and the fifth to tenth most common causative pathogen in
European studies (1–3, 13). Candidemia is responsible for sub-
stantialmedical and economic burdens (5). About 33 to 55%of all
episodes occur in intensive care units (ICUs) and are associated
with high ICU mortality rates and resource use (9, 13, 18). Mor-
tality rates range from 28 to 42% (16, 20), and attributable costs of
candidemia range from $35,000 to $68,000 per adult case in the
United States (5, 15, 20). Hospitalization charges due to increased
length of stay (LOS) are the major driving force behind excess
costs. Increased LOS attributable to candidemia is estimated at 10
to 20 days per episode in the United States (5). Antifungal therapy
is the next largest cost item, representing up to 10% of total costs
in treating candidemia (15). In addition, recent data showed that
initial inappropriate antifungal therapy was a major cause of in-
creased LOS and costs as well as poor outcomes, which suggests
the importance of appropriate first-line antifungal therapy in the
treatment of invasive candidiasis (21).
However, most data in previous studies were from the United
States, where the health insurance system, as well as treatment
strategies for invasiveCandida infection differ from those of other
countries worldwide. Although the 2009 guidelines for candi-
demia treatment by the Infectious Diseases Society of America
recommend echinocandins as the first-line antifungal agents in
the setting of neutropenia or moderate to severe illness (12), these
drugs are not widely used worldwide as first-line agents due to
their relatively high costs, especially in resource-limited countries
(6, 10). Fluconazole is still themost widely used drug, and ampho-
tericin B deoxycholate is also frequently used for broader coverage
of candidemia. With scarce data comparing the efficacy and cost-
effectiveness of these antifungal agents, additional comparative
analyses would add valuable knowledge to this issue. The assess-
ment of the economic burden attributable to the treatment of
candidemia and major contributing factors that lead to increased
costs are important because better treatment strategies may be
justified based on such data.
The primary aims of the present study were to estimate the
costs directly associated with the treatment of candidemia and to
identify modifiable factors that lead to increased costs. The sec-
ondary aimwas to assess the clinical impact of first-line antifungal
agents on the treatment outcomes of candidemia in terms ofmor-
tality, costs, and hospital LOS.
MATERIALS AND METHODS
Study design and patient sample. We designed a retrospective, cost-of-
illness study that examined the costs attributable to candidemia in 200
patients treated at four university-affiliated tertiary hospitals in South
Korea: SamsungMedical Center and Yonsei UniversityMedical Center in
Seoul, Kyungpook National University Hospital in Daegu, and Chonnam
National University Hospital in Gwangju. From each hospital, 50 consec-
utive patients who had candidemia and received antifungal treatment
from July 2008 to June 2009 were included in the study. Using the elec-
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tronic medical record system of each hospital, patients aged 18 years or
older with positive blood cultures for Candida species were identified.
Exclusion criteria were patients who were not treated with antifungal
agents or who died too early to receive antifungal agents. One patient was
excluded from final data analyses due to coinfection with invasive asper-
gillosis and recurrent episodes of bacterial sepsis. The study protocol was
approved by the local Institutional Review Board of each institution.
Data collection.For all patients, demographic characteristics, baseline
clinical characteristics of candidemia episodes, resource utilization during
candidemia treatment, length of stay, treatment outcome, and survival
data were collected retrospectively. Treatment outcome was assessed as
either treatment success or failure. Treatment success was defined as im-
provement in symptoms and signs of infection or negative conversion of
candidemia. Failure was defined as persistence or progression of symp-
toms and signs of infection, persistent candidemia, a change of antifungal
agent due to poor clinical response, or death during antifungal therapy.
Survival outcome was measured as 30-day all-cause mortality rate.
Resource utilization. Resource use was measured for all patients and
divided into six categories: hospitalization, medication and antifungal
drugs, imaging tests, laboratory tests, procedures or surgery, and other
medical treatment (dialysis, use of infusion pump, electrocardiogram
monitoring, oxygen supply, mechanical ventilation, and consultation).
The number of units consumed by each patient wasmultiplied by the cost
per unit of each resource to estimate the direct costs for each patient. Since
the four hospitals in the present study are rated as superior general hos-
pitals in Korea, additional 30% of costs are charged for every resource
provided (total costs the number of units consumed the unit cost
1.3). The unit cost of each resource was obtained from the health insur-
ance fee schedule of Korea (Korea Health Insurance Review and Assess-
ment Service, 2010), and the medication cost was estimated from the
weighted average cost (from 2009). The cost of treating adverse reactions
to antifungal therapy was estimated from resource utilization data sup-
plied by the investigators of each institution. All costs were calculated in
2009 Korean currency (KRW) and then converted into 2009 U.S. dollars
(US$). The 2009 exchange rate for $1 (hereafter, all dollar values refer to
US$) was KRW 1,156.
Although caspofungin and voriconazole were approved by Korean
Food and Drug Administration in 2001 and micafungin was approved in
2006 (10), the use of these drugs as first-line agents in the treatment of
invasive candidiasis or candidemia was limited due to their higher cost.
Fluconazole or amphotericin B deoxycholate is admitted as first-line
agents againstCandida infection inKorea, and echinocandins admitted in
the setting of treatment failure or toxicities of which criteria are defined by
HIRA (health insurance review and assessment).
Statistical analysis.Continuous variables such as cost, age, and length
of hospital stay were expressed either as means and standard deviations
(SD) for variables with normal distributions or as medians and ranges for
variables with skewed distributions. Categorical variables were expressed
as proportions and percentages. Student t tests or Mann-Whitney U tests
were used to compare continuous variables, and 2 or Fisher exact tests
were used to compare categorical variables. To define risk factors formor-
tality, multivariate logistic regression analysis and adjusted odds ratio
(OR) with 95% confidence interval (CI) were calculated. Variables that
were associated with mortality in univariate analyses with a P value of
0.10 were entered into multivariate analysis. Comparisons of costs for
each clinical variable were done using Student t tests orMann-Whitney U
tests, and then multiple linear regression analyses were used to define
independent drivers for elevated costs. All reported P values were two
tailed, and P 0.05 was considered statistically significant. The data anal-
yses were performed using PASW Statistics, version 18.0 (SPSS, Inc., Chi-
cago, IL).
RESULTS
Patient characteristics. A total of 199 patients were included in
the analysis: 50 patients from each hospital, except for one hospi-
tal from which 49 patients were included (Table 1). Of the 199
patients, 106 (53.3%) were male, and the median age was 68 years
(range, 34 to 88 years). The majority of patients (103 patients,
51.8%) had malignancies as underlying diseases. Sixty-eight
(34.2%) underwent surgery during the admission before the onset
of candidemia. The most common species was Candida albicans
(90 patients, 45.2%), followed by C. tropicalis (51 patients,
25.6%), C. parapsilosis (29 patients, 14.6%), and C. glabrata (19
patients, 9.5%).
Treatment outcomes. Fluconazole was most commonly used
as a first-line antifungal agent in 130 (65.3%) of the patients, fol-
lowed by amphotericin B deoxycholate in 61 patients (30.7%),
liposomal amphotericin B in 7 patients (3.5%), and itraconazole
TABLE 1 Baseline characteristics of study population with candidemia
Patient characteristics
Population data
(n 199)a
Gender, male 106 (53.3)
Median age in yrs (range) 68 (27–88)
Underlying disease
Cancer 103 (51.8)
Solid tumor 80 (40.2)
Hematologic disease 23 (11.6)
Transplantation 8 (4.0)
Solid organ transplantation 5 (2.5)
Bone marrow transplantation 3 (1.5)
AIDS 1 (0.5)
Surgery 68 (34.2)
Chronic lung disease 40 (20.1)
Cerebrovascular disease 34 (17.1)
Diabetes mellitus 32 (16.1)
ICU-acquired candidemia 72 (36.2)
Need for mechanical ventilation 53 (26.6)
Identified species
C. albicans 90 (45.2)
C. tropicalis 51 (25.6)
C. parapsilosis 29 (14.6)
C. glabrata 19 (9.5)
Others 10 (5.0)
First-line antifungal agent
Fluconazole 129 (64.8)
Amphotericin B deoxycholate 56 (28.1)
Liposomal amphotericin B 7 (3.5)
Itraconazole 3 (1.5)
Antifungal switch to second-line agents or more 59 (29.6)
Overall treatment success rate 105 (52.8)
Toxicity during antifungal treatmentb
Renal 34 (17.1)
Hepatic 33 (16.6)
Median duration of antifungal therapy in days (range) 15 (1–62)
30-Day mortalityc 81/169 (47.9)
a Data are expressed as the number of patients (%), unless described otherwise in
column 1.
b Renal toxicity was defined as a1.5-fold increase in the serum creatinine level above
the baseline. Hepatic toxicity was defined as a2.5-fold increase in the serum
aminotransferase level above the baseline.
c A total of 30 patients lost to follow-up before day 30 were excluded.
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in 3 patients (1.5%). The median interval from candidemia onset
to the start of antifungal drug treatment was 2 days (range, 0 to 21
days). The median total duration of antifungal agents was 15 days
(range, 1 to 62 days). Fifty-nine (29.6%) patients switched to sec-
ond-line antifungal agents due to treatment failures (n  20),
adverse events due to first-line agents (n 23), or other reasons.
Renal or hepatic adverse events occurred in 56 (28.1%) patients.
Eight (14.3%) patients changed antifungal agents due to renal
toxicity, and two (3.6%) patients changed due to hepatic toxicity.
The overall treatment success rate was 52.8% (105 of 199 pa-
tients), whereas 92 (46.2%) failed antifungal treatment, and 2
were undetermined. Themost common reason for treatment fail-
ure was death during antifungal treatment (75 of 92 patients,
81.5%).
Of the 199 patients, 30 were lost to follow-up before day 30,
with their clinical outcome unknown. Of the 169 patients who
were followed up until 30 days from the onset of candidemia, the
overall 30-day mortality rate was 47.9% (81 of 169 patients died
within 30 days of the onset of candidemia). In univariate analysis,
hematologic disease, the presence of central venous catheter, the
ICU stay at the onset of candidemia, the need for mechanical
ventilation, and treatment failure of first-line antifungal drugs
were associated with 30-day mortality (Table 2). Since the defini-
tion of first-line treatment failure also included death during an-
tifungal treatment, we excluded patients who died within 30 days
of first-line treatment and repeated the analysis. Even after exclud-
ing such patients, first-line antifungal treatment failure was a sig-
nificant risk factor for mortality in univariate analysis. In multi-
variate analysis, hematologic diseases (OR, 5.18; 95% CI, 1.06 to
25.46; P 0.043), need formechanical ventilation (OR, 6.76; 95%
CI, 2.11 to 21.66; P 0.001), and first-line treatment failure (OR,
5.13; 95% CI 1.78 to 14.80; P 0.002) remained statistically sig-
nificant risk factors for mortality.
Cost analysis. The mean total hospital costs from the first an-
tifungal therapy until the end of treatment were $4,743 (SD,
$7,049) per patient. Hospital stay, antifungal agent, and resources
for medical treatment represented themajority of total costs, with
each making up a similar proportion (Table 3). Total costs were
higher in the setting of ICU onset, central venous catheterization,
and antifungal switch to second-line agents or more (Table 4).
Age, underlying diseases, Candida species, and treatment success
were not associated with increased costs. Multiple linear regres-
sion analysis showed that ICU onset candidemia and antifungal
switch to second-line agents or more were independent risk fac-
tors for increased total costs for the treatment of candidemia (P
0.001).
TABLE 2 Risk factors for 30-day mortality of candidemia in univariate and multivariate analysis
Patient characteristics
Population dataa
P
Multivariate analysis
Survival (n 88) Death (n 81) OR (95% CI) P
Gender, male 47 (53.4) 42 (51.9) 0.839
Median age in yrs (range) 68.5 (34–88) 67 (38–85) 0.287
Underlying disease
Cancer 42 (47.7) 51 (63.0) 0.047
Solid tumor 38 (43.2) 32 (39.5) 0.628
Hematologic disease 4 (4.5) 19 (23.5) 0.001 5.182 (1.055–25.457) 0.043
Transplantation 3 (3.4) 5 (6.2) 0.482
Surgery 33 (37.5) 24 (29.6) 0.280
Diabetes mellitus 11 (12.5) 19 (21.0) 0.138
Central venous catheterization 41 (46.6) 51 (63.0) 0.033 0.554 (0.165–1.860) 0.339
Acquisition site of candidemia
General ward 60 (68.2) 43 (53.1) 0.044
Intensive care unit 28 (31.8) 38 (46.9)
Candida species
C. albicans 37 (42.0) 35 (43.2) 0.878
Non-albicans Candida 51 (58.0) 46 (56.8)
Disease severity
Need for mechanical ventilation 17 (19.3) 32 (39.5) 0.004 6.761 (2.110–21.659) 0.001
Need for oxygen supply 39 (44.3) 40 (49.4) 0.510
Need for dialysis 11 (12.5) 14 (17.3) 0.382
First-line antifungal drug
Fluconazole 58 (65.9) 47 (58.0) 0.291
Amphotericin B deoxycholate 25 (28.4) 29 (35.8) 0.303
Antifungal switch to second-line or more 27 (30.7) 26 (32.1) 0.843
Treatment failure of first-line antifungal agentsb 30/88 (34.1) 26/33 (78.8) 0.001 5.133 (1.780–14.797) 0.002
a Data are expressed as the number of patients (%), unless described otherwise in column 1.
b A total of 48 patients who died on their first-line antifungal treatment within 30 days were excluded.
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When we compared the costs between patients who were
treated with fluconazole and those who were treated with ampho-
tericin B deoxycholate as first-line antifungal drugs, the mean to-
tal costs were not different, norwere themean daily costs. Looking
further into the detailed resource utilization patterns, antifungal
drug costs were significantly lower in the amphotericin group,
whereas the costs for other medical treatments were significantly
higher in the amphotericin group, resulting in a net balance of
total costs between the two groups (Table 5).
Length of hospital stay. The median LOS after the treatment
of candidemia was 14 days (range, 1 to 62 days). No factors were
associated with an increased LOS. Choice of first-line antifungal
agent between fluconazole and amphotericin B did not influence
LOS, nor did failure of first-line antifungal agents. However, total
LOS and ICU LOS were significantly longer in patients who
switched their first-line antifungal agents to second-line drugs or
more (Table 6).
DISCUSSION
In this retrospective cost-of-illness study of candidemia, the cost
of hospitalization, antifungal drugs, and othermedical treatments
each comprised about 25% of the total costs for the treatment of
candidemia, which is in contrast to data from the United States,
where costs for hospitalization account for up to 90% of the total
costs. Regarding the cost-increasing factors, ICU-onset candi-
demia and an antifungal switch to second-line agents or more for
any reason were associated with increases in the total costs. With
regard to themean daily cost, ICU onset candidemia, hematologic
malignancy, the presence of a central venous line, non-albicans
species, and the failure of first-line antifungal drugs were associ-
ated with increases in daily costs. The success of first-line antifun-
gal therapy was found to be the only modifiable cost factor in the
present study.
The reason why hospitalization costs in Korea formed a rela-
tively small portion of the total costs being compared to those
from the United States can be explained by differences in the
healthcare finance systems of the two countries. Korean medical
insurance system is public, patients usually pay only a small por-
tion (5 to 20%) of the total costs and the rest is paid by the gov-
TABLE 3 Total cost for the treatment of candidemia per patient
Resource utilization
Cost (US$)
Proportion
(%)Mean SD
Antifungal agents 1,114 2,585 23.50
Hospital stay 1,089 1,109 23.00
Laboratory tests 581 515 12.20
Imaging 302 500 6.40
Intervention or surgery 141 297 3.00
Othera 1,414 3,122 29.80
a “Other” includes dialysis, blood transfusion, mechanical ventilation,
electrocardiogram monitoring, oxygen supply, consultation, etc.
TABLE 4 Total cost for the treatment of candidemia per patient
Variable Subvariablea
Cost (US$)
PMean SD Median Minimum Maximum
Gender Male (n 106) 4,110 3,927 3,091 112 28,177 0.199
Female (n 93) 5,463 9,399 2,570 273 61,471
Age 60 yrs (n 57) 5,929 10,952 2,671 430 61,471 0.272
60 yrs (n 142) 4,266 4,618 2,753 112 32,660
Underlying disease Cancer (n 103) 3,920 3,724 2,558 273 22,490 0.097
No cancer (n 96) 5,625 9,335 3,091 112 61,471
Solid tumor vs. hematologic disease Solid tumor (n 80) 3,703 3,824 2,383 273 22,490 0.274
Hematologic disease (n 23) 4,672 3,322 3,642 781 11,868
Candidemia onset GW onset (n 123) 2,753 2,218 2,172 112 13,022 0.001
ICU onset (n 76) 7,962 10,304 5,460 718 61,471
Candida species C. albicans (n 90) 4,004 4,750 2,576 273 32,660 0.18
Non-albicans (n 109) 5,353 8,466 3,012 112 61,471
CVC CVC (n 103) 5,798 7,363 3,537 350 57,690 0.028
No CVC (n 96) 3,610 6,546 2,377 112 61,471
Antifungal switch to second-line or moreb No switch (n 101) 4,044 3,784 2,895 450 29,476 0.005
Antifungal switch (n 43) 10,203 13,376 6,429 802 64,305
First-line antifungal agent Fluconazole (n 129) 4,292 4,965 2,617 112 32,660 0.696
Amphotericin B deoxycholate (n 56) 4,010 3,172 2,684 350 11,868
First-line treatment outcome Success (n 80) 4,467 6,884 3,204 508 61,471 0.631
Failure (n 118) 4,960 7,203 2,541 112 57,690
a GW, general ward; CVC, central venous catheterization.
b Patients who died within 14 days were excluded from the analysis.
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ernment. Government organizations are responsible for setting
the price of medical resources as well. The cost of hospital stay per
day in superior general hospitals in Korea was $28.2 for non-ICU
ward and $83.7 for ICU, while the cost per day in U.S. hospitals
was calculated as $1,383 for the non-ICU ward and $2,726 for the
ICU in one study (14). Although hospitalization cost is not a ma-
jor cost driver here, we consider that increased costs due to a
switch to second-line agentsmight be due to an increased hospital
stay (Table 6), and this finding is consistent with data from the
United States in that an increase in hospital stay was associated
with major costs (5, 15).
The importance of first-line therapy for candidemia has been de-
scribed in previous studies. Inappropriate initial therapy for candi-
demiawas associatedwithprolongedLOSand increasedcosts (1, 21).
Significant additional costs and resources use were observed when
second-line treatment was required in patients treated with flucona-
zole (4). The results of the present study support the finding that an
antifungal switch to second-line agents or more is a significant cost-
increasing factor in Korea, where hospitalization costs are relatively
low. Improvements in the appropriate selection of initial antifungal
agents by empirical use of echinocandins was even more cost-effec-
tive than the use of fluconazole (22) or amphotericin B deoxycholate
(19) in model simulation studies, despite the higher costs of echino-
candins compared to fluconazole or amphotericin B deoxycholate.
Conflicting data have been published about the relationship
between first-line therapy and survival. A prospective case-control
study showed that inadequate initial therapy and high APACHE
score were independent variables associated with mortality (2),
and a retrospective study showed that patients who switched to
second-line antifungal had a higher mortality rate (34.5%) than
patients without antifungal switch (25.1%) (P  0.001) (4). An-
other study found that a longer time from culture positivity to
antifungal initiation was associated with mortality in cancer pa-
tients with candidemia (17). However, two studies found that in-
appropriate initial therapy was not associated with mortality (1,
11), and one study demonstrated a tendency of lower mortality
with appropriate initial therapy (21). In the present study, the
failure of first-line antifungal therapy was an independent risk
factor for mortality. Although we did not evaluate the appropri-
ateness of initial therapy, our data emphasize the importance of
choosing initial antifungal agents with lower probability of failure
in order to decrease mortality.
Controversy remains as to which first-line drug is the most
cost-effective. Although echinocandins appear to be more cost-
TABLE 5 Comparison of cost between fluconazole (n 129) and amphotericin B deoxycholate (n 56) as a first-line antifungal treatment
Resource utilization Druga
Cost (US$)
PMean SD Median Minimum Maximum
Total cost FLUC 4,292 4,965 2,617 112 32,660 0.696
AMB 4,010 3,172 2,684 350 11,868
Total daily cost FLUC 259 185 199 40 1,166 0.081
AMB 343 334 218 37 1,750
Total hospitalization cost FLUC 1,125 1,072 690 37 5,441 0.491
AMB 882 703 730 127 3,399
Antifungal drug cost FLUC 1,095 1,625 710 37 10,397 0.001
AMB 438 459 271 16 2,229
Lab test FLUC 544 465 402 10 2,475 0.658
AMB 574 328 473 41 1,375
Imaging test cost FLUC 336 575 176 0 4,568 0.064
AMB 227 227 166 0 1,043
Procedures or surgery FLUC 147 319 19 0 2,318 0.086
AMB 90 131 24 0 614
Other medical treatment FLUC 976 2,426 80 0 17,436 0.045
AMB 1,732 2,121 501 5 8,632
a FLUC, fluconazole; AMB, amphotericin B deoxycholate.
TABLE 6 Comparison of lengths of hospital staya
Facility
First-line treatment regimen First-line treatment result Switch to second-line agents or more
FLUC AMB P Success Failure P No switch Switch P
Hospital stay 19 (4–62) 19 (3–29) 0.593 18 (4–62) 20.5 (3–61) 0.224 18 (3–62) 21 (5–61) 0.037
ICU stayb 20 (2–50) 18 (1–29) 0.594 16.5 (2–52) 33 (1–61) 0.002 19 (2–44) 29 (1–61) 0.009
a Data are median numbers of days (range). FLUC, fluconazole; AMB, amphotericin B deoxycholate. Patients who died within 30 days of treatment were excluded from the
analysis.
b Patients who never stayed in the ICU were excluded.
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effective than fluconazole or amphotericin B in the United States
(19, 22), they have not been approved as first-line drugs by the
Korea Food andDrug Administration due to the fact that the drug
unit cost for amphotericin Bdeoxycholate is the lowest. Given that
clinical decisions regarding drug choice are complicated by factors
such as host immunity, Candida species, drug efficacy, and cost,
data for direct cost comparisons between fluconazole and ampho-
tericin B are scarce (7). Our data show that amphotericin Bwas no
more cost-effective than fluconazole. Fluconazole and amphoter-
icin B did not differ in total cost and cost per day. Even though the
cost of amphotericin B was less than that of fluconazole, other
medication costs and lab test costs were higher in the amphoteri-
cin B group, leading to a net zero balance between fluconazole and
amphotericin B. Although 30-day mortality was not different, the
treatment success rates were significantly lower when amphoteri-
cin B was used as first-line therapy (15/56 [26.8%] with ampho-
tericin B versus 60/129 [46.5%] with fluconazole, P 0.011).
With regard to the choice between fluconazole and amphoter-
icin B deoxycholate, we could not determine the exact reason why
clinicians prescribed one agent versus another as initial therapy.
However, we can presume that amphotericin B deoxycholate was
preferred in patients with more serious illness (Table 7). Patients
whowere started on amphotericin B deoxycholate had underlying
cancer, CVC, or mechanical ventilation more frequently that
those who were started on fluconazole, suggesting that amphoter-
icin B is given in more critical patients. This finding is also consis-
tent with current practice of clinicians in Korea. Although echi-
nocandins and liposomal amphotericin B are not admitted as
first-line agents against invasive candidiasis or candidemia in
Korea, we usually prescribe fluconazole for the treatment of
candidemia. Amphotericin B deoxycholate is chosen when it is
considered necessary for broader spectrum of coverage or for im-
munocompromised hosts. Some may presume that the loss of
cost-effectiveness of amphotericin B compared to fluconazole in
this study could be partially explained by the increase in other
medical treatment costs because disease severity in amphotericin
B deoxycholate group might have been worse. However, signifi-
cantly higher rate of treatment failure and rate of switch to second-
line antifungal agents with the use amphotericin B was seen, and
these have led to increased costs.
Among the limitations of the present study is its retrospective
nature. First, since 30 patients were lost to follow-up prior to day
30, 30-day mortality data were available only for 169 subjects,
limiting the results of the mortality analysis. Important clinical
variables that would have been associated with mortality were not
collected. For example, the APACHE II score, which is the only
independent predictor of mortality of candidemia in one study
(11), could not be calculated. Other clinical indices, such as the
SOFA or SAPS II score, also were not available. Instead, we used
indirect measures for disease severity, such as underlying malig-
nancies, ICU acquisition of candidemia, central venous catheter-
ization, and the need for mechanical ventilation (Table 2). Sec-
ond, the appropriateness of antifungal therapy also was not
assessable since antifungal susceptibility tests were not available at
most institutions. However, we believe that most therapies might
have been appropriate because the fluconazole resistance rate
amongCandida species in Korea is low (0.8%); for example, the
resistance rate ofC. glabratawas 2.8% (8). Third, calculation of an
exact estimate of costs attributable only to candidemia was com-
plicated by other comorbidities that might have overlapped can-
didemia in resource utilization. Fourth, the sample size was rela-
tively small, whichmight compromise the ability to generalize our
results. However, we collected data at four different institutions
from three provinces in Korea to overcome the small sample size
and construct a representative sample. Fifth, the four university-
affiliatedmedical centers in the present study are rated as superior
general hospitals in Korea, whichmeans that an additional 30%of
fees are charged for every medical resource provided. Total costs
for treatment of candidemia may be cheaper in smaller hospitals
or private clinics. However, given that candidemia occurs mostly
in nosocomial settings or critically ill patients, we believe our data
could reflect the real practice. Finally, since patients who were not
treated with antifungal agents or who died too early to receive
antifungal agents were excluded from the study, the clinical out-
comes of our study are not representative of all cases of candi-
demia.
Despite these limitations, this is the first study to estimate
the attributable costs for treating candidemia in Korea, encom-
TABLE 7 Comparison of clinical characteristics of patients treated with
fluconazole and amphotericin B deoxycholate prescribed as a first-line
agent
Clinical patient characteristics
Treatmenta
P
Fluconazole
(n 129)
Amphotericin B
(n 56)
Gender, male 70 (54.3) 31 (55.4) 0.891
Median age in yrs (range) 69 (27–85) 66.5 (38–87) 0.298
Underlying disease
Cancer 56 (43.4) 41 (73.2) 0.001
Solid tumor 50 (38.8) 29 (51.8) 0.100
Hematologic malignancy 6 (4.7) 12 (21.4) 0.001
Transplantation 2 (1.6) 4 (7.1) 0.069
Solid organ transplantation 1 (0.8) 2 (3.6) 0.218
Bone marrow
transplantation
1 (0.8) 2 (3.6) 0.218
Surgery 49 (38.0) 15 (26.8) 0.141
Diabetes mellitus 25 (19.4) 6 (10.7) 0.147
ICU-acquired candidemia 53 (41.1) 16 (28.6) 0.106
Identified species, C. albicans 64 (49.6) 23 (41.4) 0.285
Need for mechanical ventilation 26 (20.2) 20 (35.7) 0.024
Central venous catheterization 49 (38.0) 42 (75.0) 0.001
Infusion pump use 78 (60.5) 42 (75.0) 0.057
Consultation 105 (81.4) 53 (94.6) 0.019
Transfusion 53 (41.1) 34 (60.7) 0.014
Complications during antifungal
treatment
Hypokalemia 20 (15.5) 16 (28.6) 0.039
Nephrotoxicity 16 (12.4) 13 (23.2) 0.063
Hepatotoxicity 22 (17.1) 9 (16.1) 0.869
Switch to second-line treatment 22 (17.1) 28 (50.0) 0.001
Treatment failure of first-line
agent
68 (52.7) 41 (73.2) 0.011
Median duration of first-line
treatment
13 (1-62) 9 (2-27) 0.020
Death during first-line treatment 12 (9.3) 5 (8.9) 0.936
30-Day mortality 46 (44.7) 29 (53.7) 0.281
a Data are expressed as the number of patients (%), unless described otherwise in
column 1.
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passing epidemiology, treatment strategies, and outcome alto-
gether. Comparing direct costs between treatment with flucona-
zole and amphotericin B deoxycholate and demonstrating the
importance of first-line antifungal agents in association with cost
and mortality may contribute to establishing cost-effective treat-
ment strategies for candidemia in resource-poor countries. Fur-
ther studies are warranted to prospectively compare the direct
costs of amphotericin B deoxycholate to those of fluconazole and
to compare the costs of these older drugs to those of new echino-
candins in the treatment of candidemia.
Conclusion. In summary, an antifungal switch to second-line
agents for any reasonwas the onlymodifiable factor that increased
attributable costs for treating candidemia and hospital LOS in the
present study. In addition, treatment failure of first-line antifun-
gal agents was an independent risk factor formortality. Treatment
with fluconazole and amphotericin B did not differ in terms of
mortality and total costs. Our data show that the selection of ap-
propriate first-line antifungal agents is important for the reduc-
tion of medical costs and to improve outcomes.
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